brexucabtagene autoleucel
gilead sciences
['lymsm', 'brexu-cel', 'mantle,(-dismantle)', 'lymphoma', 'zuma-2']
high response rates were seen in patients with mantle cell lymphoma in a real-world study of brexu-cel that would not meet zuma-2 eligibility criteria. #asco22 #lymsm 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.